GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004560015 | Thyroid | PTC | positive regulation of fat cell differentiation | 33/5968 | 66/18723 | 1.63e-03 | 9.01e-03 | 33 |
GO:00094167 | Thyroid | PTC | response to light stimulus | 127/5968 | 320/18723 | 1.76e-03 | 9.58e-03 | 127 |
GO:19019898 | Thyroid | PTC | positive regulation of cell cycle phase transition | 52/5968 | 115/18723 | 1.82e-03 | 9.84e-03 | 52 |
GO:00004665 | Thyroid | PTC | maturation of 5.8S rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) | 15/5968 | 24/18723 | 1.95e-03 | 1.05e-02 | 15 |
GO:004354219 | Thyroid | PTC | endothelial cell migration | 112/5968 | 279/18723 | 2.03e-03 | 1.09e-02 | 112 |
GO:19058184 | Thyroid | PTC | regulation of chromosome separation | 35/5968 | 72/18723 | 2.23e-03 | 1.18e-02 | 35 |
GO:0070527111 | Thyroid | PTC | platelet aggregation | 33/5968 | 67/18723 | 2.24e-03 | 1.18e-02 | 33 |
GO:00359875 | Thyroid | PTC | endodermal cell differentiation | 24/5968 | 45/18723 | 2.28e-03 | 1.20e-02 | 24 |
GO:00709322 | Thyroid | PTC | histone H3 deacetylation | 13/5968 | 20/18723 | 2.37e-03 | 1.24e-02 | 13 |
GO:00311253 | Thyroid | PTC | rRNA 3'-end processing | 8/5968 | 10/18723 | 2.46e-03 | 1.27e-02 | 8 |
GO:00450505 | Thyroid | PTC | protein insertion into ER membrane by stop-transfer membrane-anchor sequence | 8/5968 | 10/18723 | 2.46e-03 | 1.27e-02 | 8 |
GO:00903055 | Thyroid | PTC | nucleic acid phosphodiester bond hydrolysis | 105/5968 | 261/18723 | 2.53e-03 | 1.31e-02 | 105 |
GO:00718872 | Thyroid | PTC | leukocyte apoptotic process | 48/5968 | 106/18723 | 2.58e-03 | 1.32e-02 | 48 |
GO:00300714 | Thyroid | PTC | regulation of mitotic metaphase/anaphase transition | 30/5968 | 60/18723 | 2.60e-03 | 1.33e-02 | 30 |
GO:00215373 | Thyroid | PTC | telencephalon development | 100/5968 | 248/18723 | 2.90e-03 | 1.44e-02 | 100 |
GO:00002804 | Thyroid | PTC | nuclear division | 167/5968 | 439/18723 | 3.27e-03 | 1.60e-02 | 167 |
GO:0051346112 | Thyroid | PTC | negative regulation of hydrolase activity | 146/5968 | 379/18723 | 3.33e-03 | 1.62e-02 | 146 |
GO:0045861113 | Thyroid | PTC | negative regulation of proteolysis | 136/5968 | 351/18723 | 3.54e-03 | 1.71e-02 | 136 |
GO:20001345 | Thyroid | PTC | negative regulation of G1/S transition of mitotic cell cycle | 39/5968 | 84/18723 | 3.66e-03 | 1.76e-02 | 39 |
GO:00442726 | Thyroid | PTC | sulfur compound biosynthetic process | 63/5968 | 148/18723 | 3.91e-03 | 1.87e-02 | 63 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0517122 | Liver | Cirrhotic | Coronavirus disease - COVID-19 | 136/2530 | 232/8465 | 3.28e-20 | 1.82e-18 | 1.12e-18 | 136 |
hsa046102 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa0481021 | Liver | Cirrhotic | Regulation of actin cytoskeleton | 100/2530 | 229/8465 | 5.28e-06 | 5.50e-05 | 3.39e-05 | 100 |
hsa0517132 | Liver | Cirrhotic | Coronavirus disease - COVID-19 | 136/2530 | 232/8465 | 3.28e-20 | 1.82e-18 | 1.12e-18 | 136 |
hsa046103 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa0481031 | Liver | Cirrhotic | Regulation of actin cytoskeleton | 100/2530 | 229/8465 | 5.28e-06 | 5.50e-05 | 3.39e-05 | 100 |
hsa0502022 | Liver | HCC | Prion disease | 195/4020 | 273/8465 | 3.26e-16 | 1.56e-14 | 8.67e-15 | 195 |
hsa0517142 | Liver | HCC | Coronavirus disease - COVID-19 | 167/4020 | 232/8465 | 1.50e-14 | 4.19e-13 | 2.33e-13 | 167 |
hsa046104 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
hsa0481041 | Liver | HCC | Regulation of actin cytoskeleton | 134/4020 | 229/8465 | 4.48e-04 | 1.94e-03 | 1.08e-03 | 134 |
hsa0502032 | Liver | HCC | Prion disease | 195/4020 | 273/8465 | 3.26e-16 | 1.56e-14 | 8.67e-15 | 195 |
hsa0517152 | Liver | HCC | Coronavirus disease - COVID-19 | 167/4020 | 232/8465 | 1.50e-14 | 4.19e-13 | 2.33e-13 | 167 |
hsa046105 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
hsa0481051 | Liver | HCC | Regulation of actin cytoskeleton | 134/4020 | 229/8465 | 4.48e-04 | 1.94e-03 | 1.08e-03 | 134 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
C7 | SNV | Missense_Mutation | | c.2353N>C | p.Glu785Gln | p.E785Q | P10643 | protein_coding | tolerated(1) | benign(0) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
C7 | SNV | Missense_Mutation | | c.320C>T | p.Ser107Phe | p.S107F | P10643 | protein_coding | tolerated(0.21) | possibly_damaging(0.77) | TCGA-AN-A0XW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
C7 | SNV | Missense_Mutation | rs376674018 | c.148N>T | p.Arg50Trp | p.R50W | P10643 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-AO-A03T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
C7 | SNV | Missense_Mutation | | c.1639N>C | p.Asp547His | p.D547H | P10643 | protein_coding | deleterious(0) | probably_damaging(0.966) | TCGA-C8-A12P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
C7 | SNV | Missense_Mutation | | c.2037G>C | p.Trp679Cys | p.W679C | P10643 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D8-A1JK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
C7 | SNV | Missense_Mutation | | c.944T>C | p.Val315Ala | p.V315A | P10643 | protein_coding | tolerated(0.31) | benign(0.207) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
C7 | SNV | Missense_Mutation | rs766182545 | c.2353N>A | p.Glu785Lys | p.E785K | P10643 | protein_coding | tolerated(0.07) | benign(0.003) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
C7 | SNV | Missense_Mutation | novel | c.2451N>T | p.Glu817Asp | p.E817D | P10643 | protein_coding | deleterious(0.01) | probably_damaging(0.971) | TCGA-GI-A2C9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | | SD |
C7 | insertion | Frame_Shift_Ins | novel | c.1744_1745insGCATTAATCAGTATCTCTTGACTGAGGAAGC | p.Val582GlyfsTer14 | p.V582Gfs*14 | P10643 | protein_coding | | | TCGA-AN-A0FV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
C7 | insertion | In_Frame_Ins | novel | c.2350_2350+1insCTCTGA | p.Ala784_Glu785insLeuThr | p.A784_E785insLT | P10643 | protein_coding | | | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |